Clinical Trial

Effect of Saccharomyces Boulardii CNCM I-745 on Gut Microbiota in Patients Undergoing Antibiotic Therapy (in the Context of Erythema Migrans (Early Skin Form of Lyme Borreliosis))

Study acronym: SUBLYME
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The aim of this study is to assess the effect of Saccharomyces boulardii CNCM I-745 on gut microbiota in patients undergoing antibiotic therapy (in the context of erythema migrans (early skin form of Lyme borreliosis)).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-06-07; most recent amendment 2025-08-21.
Status change: Not Yet Recruiting → Recruiting 2025-08-21
Trial Details
NCT Number NCT06451913
Lead Sponsor Biocodex
Conditions Erythema Migrans of Lyme Disease
Enrollment 120 participants
Start Date 2025-07-16
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-08-27